Deep Neuromuscular Blockade on Postoperative Pain
Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Nov 6, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how different levels of muscle relaxation, known as neuromuscular blockade, affect pain after surgery in young children. Specifically, it focuses on children aged 2 months to under 7 years who are scheduled to have laparoscopic surgery, which is a type of minimally invasive surgery done with small incisions. The goal is to understand how varying degrees of muscle relaxation during surgery might change the amount of pain these children feel afterward.
To be eligible for this study, children must be in good health, classified as ASA Physical Status I, II, or III, meaning they have no major health issues. However, children who are having emergency surgery, have chronic pain, or have certain medical conditions, such as heart problems or muscle disorders, cannot participate. If chosen to take part in the trial, families can expect close monitoring and care during and after the surgery, with the aim of improving pain management for pediatric patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Pediatric patients aged over 2 months to under 7 years scheduled for laparoscopic surgery under general anesthesia.
- • American Society of Anesthesiologists (ASA) Physical Status Classification I, II, or III.
- Exclusion Criteria:
- • Patients undergoing emergency surgery.
- • Patients with chronic pain or currently taking analgesics for chronic pain.
- • Known hypersensitivity to general anesthetic agents or analgesics.
- • Patients with underlying cardiovascular disease.
- • Patients with neuromuscular disorders.
- • Any other condition that, in the investigator's judgment, would make the patient unsuitable for participation in the study.
About Seoul National University Hospital
Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported